U.S. stock index futures edged higher on Sunday evening as investors engaged in dip-buying after steep losses on Friday. The ...

CPI inflation, retail sales, Jerome Powell congressional testimony, along with earnings from Coca-Cola, McDonald’s, Cisco, ...

This was the stock's second consecutive day of losses.

If the attention generated by BioSpace’s coverage of this landmark approval is any indication, Americans are hungry for ...

The stock's fall snapped a four-day winning streak.

A new non-opioid painkiller, suzetrigine , has just been approved by the US drug regulator, the FDA. It is the first non-opioid painkiller the agency ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...

Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...